1 Reason Why Shares of Johnson & Johnson Are Surging This Month
A spate of promising news is helping to extend a post-earnings rally for the healthcare giant's shares.
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
XOMA Royalty Completes Acquisition of LAVA Therapeutics. Brings 2 partnered assets into XOMA Royalty's milestone and royalty portfolio.
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - XOMA Royalty ( NASDAQ:XOMA ) , LAVA Therapeutics ( NASDAQ:LVTX )
EMERYVILLE, Calif., Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- XOMA Royalty Corporation ( "XOMA Royalty" ) ( NASDAQ:XOMA ) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. ( "LAVA" ) ( NASDAQ:LVTX ) with a ...
Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® ( golimumab )
Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global pharmaceutical company with a strategic focus on specialty, ...
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® ( golimumab )
REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global ...
A Closer Look at Johnson & Johnson's Options Market Dynamics - Johnson & Johnson ( NYSE:JNJ )
Investors with a lot of money to spend have taken a bullish stance on Johnson & Johnson ( NYSE:JNJ ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't ...
Why Johnson & Johnson's Share Price Is Popping This Month
Johnson & Johnson had strong Q3 results and reported an important acquisition.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past ...
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - ALX Oncology Holdings ( NASDAQ:ALXO ) , Erasca ( NASDAQ:ERAS )
PALM BEACH, Fla., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment paradigms for historically difficult cancers.
Don't Give Up on Dividend Stocks. 5 Dividend Kings Down Between 5% and 33% to Buy in November
Investing in equal parts of these five dividend stocks produces an average yield of 3.9%.
Johnson & Johnson ( JNJ ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms ...
Nailing Systems Market Set for Strong Growth as Demand Rises Across Orthopedic and Trauma Care Segments: Verified Market Research®
Lewes, Delaware, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- The Global Nailing Systems Market Size is projected to grow at a CAGR of 5.4% from 2026 to 2032, according to a new report published by Verified Market Research®.
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
Buy 3 Columbia Mutual Funds for Growth and Income
Consider investing in Columbia mutual funds like LBSAX, CSMIX and NLGAX to achieve balanced growth and income.
2 No-Brainer Healthcare Stocks to Buy Now
These two healthcare stocks scan as bargains right now.
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott ...
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott ...
Consumer Brands Shake Things Up...With Mergers
2025 has been quite the year for consumer brands, but not in a good way. The industry has underperformed for the past three years and many of the world's largest consumer brand companies are resorting to mergers & acquisitions, asset sales, and spin-offs to rejuvenate their prospects.
Johnson & Johnson Adds Prostate Cancer Candidate In Around $3 B Halda Deal - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson ( NYSE:JNJ ) on Monday agreed to acquire Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. Halda is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera ( RIPTAC ) platform to develop oral, targeted therapies for ...
Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute - Kenvue ( NYSE:KVUE )
On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s ( NYSE:KVUE ) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.
Nvidia and 19 Other Stocks Now Make Up 50% of the S&P 500. Here's What It Means for Your Investment Portfolio.
Buying the S&P 500 takes the belief that today's leading companies deserve their lofty valuations.
Top 3 MassMutual Mutual Funds Worth Noting
Invest in MassMutual mutual funds like MDDAX, MMGEX and MPHNX for a diversified investment approach.
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus
Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical development Additional RIPTAC™ programs in development for major solid tumor types and ...
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
The Vanguard Dividend Appreciation Index Fund ETF ( VIG ) Delivers Stronger Growth Than the iShares Core High Dividend ETF ( HDV )
The Vanguard Dividend Appreciation ETF ( NYSEMKT:VIG ) and the iShares Core High Dividend ETF ( NYSEMKT:HDV ) differ most in dividend yield, sector mix, and risk profile, with VIG offering lower costs but HDV providing notably higher income.Both funds target U.S. dividend-focused strategies, but ...
The Schwab U.S. Dividend Equity ETF ( SCHD ) Offers a Higher Yield and Lower Cost Than the iShares Core High Dividend ETF ( HDV )
The iShares Core High Dividend ETF ( NYSEMKT:HDV ) and the Schwab U.S. Dividend Equity ETF ( NYSEMKT:SCHD ) both focus on U.S. dividend stocks, but SCHD stands out for its lower cost, higher yield, and much larger assets under management, while HDV has shown stronger recent returns.Both the ...
Jana Partners push to break up Cooper Cos. could change the stock's outlook
Jana announced a top portfolio position in Cooper and plans to push for strategic alternatives, including a potential combination for its contact lens unit.
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
-Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration ( FDA ) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb & Co. ( NYSE:BMY ) , in collaboration with Johnson & Johnson ( NYSE:JNJ ) , announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care ( conventional antiplatelet therapy ) for ...
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Top Robotics Stocks to Add to Your Portfolio for Impressive Returns
Robotics is poised for robust long-term growth. Consider NVDA, TRMD and TER for potential market dominance across sectors.
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia - Legend Biotech ( NASDAQ:LEGN )
31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and immunology indications
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation ...
A Look Into Johnson & Johnson Inc's Price Over Earnings - Johnson & Johnson ( NYSE:JNJ )
In the current session, the stock is trading at $195.11, after a 0.37% increase. Over the past month, Johnson & Johnson Inc. ( NYSE:JNJ ) stock increased by 1.56%, and in the past year, by 26.69%.
Why Is Johnson & Johnson ( JNJ ) Up 1.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Decoding Johnson & Johnson's Options Activity: What's the Big Picture? - Johnson & Johnson ( NYSE:JNJ )
Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson ( NYSE:JNJ ) we detected 8 trades.
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - Salarius Pharmaceuticals ( NASDAQ:SLRX )
Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq
UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( "LAVA" ) ( Nasdaq: LVTX ) today announced that 22,877,463 of LAVA's common shares, representing approximately 87% of LAVA's outstanding common shares, were validly tendered and not withdrawn ...
Should Invesco Dow Jones Industrial Average Dividend ETF ( DJD ) Be on Your Investing Radar?
Style Box ETF report for ...
